Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2SWI8)

• Drug Name: RG7888 Drug Info
• Synonyms: MOXR0916

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
Urothelial carcinoma	2C92.0	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM2SWI8

Molecule-Related Drug Atlas

Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[3]
Amlitelimab	DMKR3BQ	Asthma	CA23	Phase 2	[4]
mRNA-2752	DMUKBI2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MEDI6383	DM1YSMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
mRNA-2416	DMFTAWU	Lymphoma	2A80-2A86	Phase 1	[7]
SAR442970	DM3DHWE	Inflammation	1A00-CA43.1	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TAX transcriptionally-activated glycoprotein 1 (OX40)	TTBW580	TNFL4_HUMAN	Not Available	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
• [3] Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
• [4] OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
• [5] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [6] J Clin Oncol 33, 2015 (suppl; abstr 3056).
• [7] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [8] Clinical pipeline report, company report or official report of Sanofi